Mach 1 Financial Group LLC Invests $787,000 in Medpace Holdings, Inc. $MEDP

Mach 1 Financial Group LLC purchased a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the 4th quarter, HoldingsChannel.com reports. The fund purchased 1,401 shares of the company’s stock, valued at approximately $787,000.

Several other institutional investors have also modified their holdings of MEDP. AQR Capital Management LLC raised its holdings in shares of Medpace by 65.1% during the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock worth $518,170,000 after acquiring an additional 404,226 shares during the period. Arrowstreet Capital Limited Partnership raised its holdings in shares of Medpace by 205.8% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after acquiring an additional 211,411 shares during the period. Wasatch Advisors LP raised its holdings in shares of Medpace by 14.0% during the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after acquiring an additional 116,354 shares during the period. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Medpace by 24,930.4% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 101,373 shares of the company’s stock worth $56,936,000 after acquiring an additional 100,968 shares during the period. Finally, Invesco Ltd. raised its holdings in shares of Medpace by 18.9% during the 3rd quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock worth $276,313,000 after acquiring an additional 85,517 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Truist Financial reduced their price target on shares of Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research report on Wednesday, February 11th. BMO Capital Markets reduced their price target on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a research report on Friday, April 24th. Leerink Partners reduced their price target on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a research report on Wednesday, February 11th. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target on the stock in a research report on Friday, February 13th. Finally, Robert W. Baird reduced their price target on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. Four equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $467.08.

Medpace Trading Up 2.0%

Shares of MEDP opened at $430.10 on Friday. The firm has a market cap of $12.28 billion, a P/E ratio of 27.03, a price-to-earnings-growth ratio of 2.14 and a beta of 1.19. Medpace Holdings, Inc. has a 12-month low of $287.17 and a 12-month high of $628.92. The company’s 50-day moving average price is $459.82 and its 200 day moving average price is $520.06.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.74 by $0.54. The firm had revenue of $706.60 million for the quarter, compared to analyst estimates of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. Medpace’s revenue was up 26.5% on a year-over-year basis. During the same period in the previous year, the firm earned $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities research analysts forecast that Medpace Holdings, Inc. will post 17.04 earnings per share for the current year.

Insider Transactions at Medpace

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total value of $14,436,197.10. Following the sale, the president owned 15,000 shares of the company’s stock, valued at $6,829,500. The trade was a 67.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 20.50% of the stock is currently owned by insiders.

Key Medpace News

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: A class action lawsuit has been filed against Medpace, with investors urged to seek lead-plaintiff status before a June 8, 2026 deadline.
• Negative Sentiment: Several law firms are publicizing claims that Medpace allegedly concealed or misrepresented cancellation-rate risks and growth expectations, increasing legal overhang.
• Negative Sentiment: The repeated investor alerts reference significant losses and a prior sharp stock decline, reinforcing concerns about potential damages and reputational impact.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.